Yet, further studies are needed to comprehensively evaluate its impact on immunotherapy efficacy, for example evaluating the efficacy of PD-1/PD-L1 antibody in the context of POPDC3 overexpression/silencing in NSCLC xenograft model in C57BL/6 mice. This evidence concerns the gene CD274 and non-small cell lung carcinoma.